Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for use in NSCLC in 2004 and pancreatic cancer in 2005 (Carter and Tadi, 2025). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.